Emil Kakkis Sells 54,404 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil Kakkis sold 54,404 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the sale, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at approximately $15,025,063.20. This represents a 7.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ultragenyx Pharmaceutical Stock Down 1.2%

Shares of NASDAQ RARE opened at $21.80 on Thursday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.41 and a 12 month high of $42.37. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -3.73 and a beta of 0.16. The business has a fifty day simple moving average of $23.56 and a 200-day simple moving average of $29.19.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The company had revenue of $207.28 million during the quarter, compared to analysts’ expectations of $199.60 million. During the same period in the prior year, the business posted ($1.39) EPS. The company’s revenue for the quarter was up 25.5% compared to the same quarter last year. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Institutional support remains in the register, which can help stabilize the float and provide long‑term demand for shares. Read More.
• Neutral Sentiment: Analyst coverage is still skewed toward buys and the company recently reported revenue beat but an EPS miss (Feb. 12). That mixed fundamental backdrop leaves the stock sensitive to news and revisions.
• Negative Sentiment: Legal overhang: multiple law firms have circulated investor notices and a securities class action has been filed alleging misstatements/omissions related to setrusumab; the lead‑plaintiff deadline (Apr. 6, 2026) concentrates attention on potential damages and litigation risk. Read More.
• Negative Sentiment: Regulatory/program risk amplified: Levi & Korsinsky highlights that RARE plunged ~42% after disclosure of a Phase III failure for setrusumab — that clinical setback remains the root cause of the stock’s heightened volatility and underpins many of the litigation claims. Read More.
• Negative Sentiment: Clustered insider selling: the CEO and several senior executives and officers disclosed large share sales (multiple filings show material blocks around $22.7–22.8), which often weighs on near‑term sentiment and raises questions for some investors. Read More.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on RARE shares. Guggenheim lowered their price objective on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Leerink Partners decreased their target price on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Bank of America dropped their price target on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, January 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Finally, Truist Financial lowered their target price on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Sixteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $68.29.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd lifted its stake in Ultragenyx Pharmaceutical by 1,116,754.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 122,854 shares of the biopharmaceutical company’s stock valued at $2,826,000 after acquiring an additional 122,843 shares during the last quarter. Alberta Investment Management Corp acquired a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at $883,000. Mercer Global Advisors Inc. ADV lifted its stake in shares of Ultragenyx Pharmaceutical by 17.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,965 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 2,036 shares during the last quarter. Krensavage Asset Management LLC bought a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth $3,442,000. Finally, Empowered Funds LLC acquired a new position in Ultragenyx Pharmaceutical during the fourth quarter worth $66,000. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.